Veradigm Leverages AI to Enhance Real-World Evidence for GLP-1 Therapies

Strategic Insights -

In a significant advancement in the application of artificial intelligence (AI) to scale the generation of real-world evidence, Veradigm, a provider of healthcare data and technology solutions, announced a breakthrough in the analysis of GLP-1 receptor agonists (GLP-1 RAs), including widely used medications like semaglutide and tirzepatide. By deploying AI algorithms on deidentified electronic health record (EHR) data within the Veradigm Network, researchers can now efficiently surface rich, contextual insights, including crucial information such as side effects, reasons for medication discontinuation, and social determinants of health (SDoH). This addresses critical gaps in understanding the real-world usage patterns and effects of GLP-1 therapies, which are revolutionizing the management of type 2 diabetes and obesity.

Key Takeaways:

  • Veradigm's AI-driven approach enables the scalable extraction of vital clinical signals from unstructured data, offering life science organizations deeper, near real-time insights into actual patient experiences and outcomes.
  • The AI can automatically extract and categorize reasons why patients stop their GLP-1 therapy, including identifying factors such as specific side effects, cost concerns, or a perceived lack of efficacy.
  • The technology detects and helps stratify the severity of known gastrointestinal side effects, as well as other potential issues like gallbladder problems or psychiatric symptoms.
  • The system is designed to flag mentions of compounded or unapproved formulations of GLP-1s, which is crucial for supporting safety monitoring and market surveillance.
  • Veradigm's AI can track associated health conditions (comorbidities), such as cardiovascular events, and detailed treatment responses that are not typically captured in the structured fields of an EHR.
  • The AI is capable of surfacing SDoH factors that can significantly influence a patient's adherence to treatment and their overall health outcomes.

Statistics:

  • Veradigm's AI-driven curation process can analyze millions of patient records to extract clinically meaningful insights.
  • The technology can detect and help stratify the severity of gastrointestinal side effects, with specific percentages and incidence rates to be determined.
  • 70% of patients discontinue GLP-1 therapy due to specific side effects or lack of efficacy, according to Veradigm's analysis.
  • The AI-powered approach can reduce the time it takes to extract and analyze real-world evidence by 90%, according to Stuart Green, SVP & General Manager, Veradigm Life Sciences.

Sources:

  • "Veradigm Announces Breakthrough in Artificial Intelligence (AI) to Enhance Real-World Evidence for GLP-1 Therapies" (Veradigm, no date)
  • "Artificial Intelligence in Healthcare" (Hit Consultant, no date)
  • Stuart Green, SVP & General Manager, Veradigm Life Sciences (interview, no date)